Is Kura Oncology Inc (KURA) overvalued? · rev $20.9M
Kura Oncology Inc (KURA) is a biotechnology company listed on NASDAQ.
This page asks whether Kura Oncology Inc (KURA) looks expensive on cached numbers — not a short thesis.
Latest reported KURA revenue for 2026-06-30 was $20.9M. Net income was -$68.3M. Revenue was up 14.3% from 2026-03-31 to 2026-06-30. KURA currently screens at market cap $861.1M.
KURA currently screens at market cap $861.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next KURA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the KURA stock page for the full model, not this heading.
Not investment advice.